Non Small Cell Lung Cancer
17 competing products in clinical development for Non Small Cell Lung Cancer.
Pipeline by Phase
Pre-clinical2
Phase 11
Phase 1/22
Phase 28
Phase 34
All Products (17)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Pemetrexed + Cisplatin + Placebo + Pemetrexed | Eli Lilly | Phase 3 | Completed | 77 |
| pemetrexed + docetaxel | Eli Lilly | Phase 3 | Completed | 77 |
| PemCarbo + Pem only | Eli Lilly | Phase 3 | UNKNOWN | 77 |
| FYB206 + FYB206 + Keytruda | Formycon AG | Phase 3 | Terminated | 69 |
| pemetrexed + erlotinib | Eli Lilly | Phase 2 | Completed | 52 |
| pemetrexed + cisplatin | Eli Lilly | Phase 2 | Terminated | 52 |
| enzastaurin + pemetrexed + docetaxel + carboplatin | Eli Lilly | Phase 2 | Completed | 52 |
| pemetrexed + gemcitabine | Eli Lilly | Phase 2 | Completed | 52 |
| enzastaurin + placebo | Eli Lilly | Phase 2 | Completed | 52 |
| pemetrexed + Best Supportive Care | Eli Lilly | Phase 2 | Completed | 52 |
| CAB-AXL-ADC + PD-1 inhibitor | BioAtla | Phase 2 | Completed | 44 |
| Tomivosertib + Pembrolizumab + Pemetrexed | eFFECTOR Therapeutics | Phase 2 | Active | 44 |
| TNG456 + abemaciclib | Eli Lilly | Phase 1/2 | Recruiting | 41 |
| CAB-ROR2-ADC + PD-1 inhibitor | BioAtla | Phase 1/2 | Completed | 33 |
| BBP-398 with nivolumab | BridgeBio Pharma | Phase 1 | Terminated | 30 |
| Selpercatinib | Eli Lilly | Pre-clinical | Completed | 23 |
| Pemetrexed | Eli Lilly | Pre-clinical | Completed | 23 |